1h-pyrrole-2-amide derivative, pharmaceutical composition and method for treating and/or preventing ythdc1-related diseases

A compound represented by Formula I, or a hydrate thereof, or a pharmaceutically acceptable salt thereof, wherein its structure is as shown below:

• Formula I
• wherein, ring A is selected from a 6- to 10-membered aromatic ring and a 5- to 10-membered heteroaromatic ring;
• in ring A, the 5- to 10-membered heteroaromatic ring contains 1 to 3 heteroatoms, wherein the heteroatoms are selected from N, S, and O;
• R1 is selected from H, halogen, cyano, halogen-substituted or unsubstituted C1-C8 alkyl, halogen-substituted or unsubstituted C1-C8 alkoxy, halogen-substituted or unsubstituted C2-C8 alkanoyl, halogen-substituted or unsubstituted C2-C8 alkoxycarbonyl, halogen-substituted or unsubstituted 3- to 8-membered cycloalkyl, substituted or unsubstituted 6- to 10-membered aryl, and substituted or unsubstituted 5- to 10-membered heteroaryl;
• in R1, the 5- to 10-membered heteroaryl contains 1 to 3 heteroatoms, wherein the heteroatoms are selected from N, S, and O;
• in R1, the substituents of the substituted or unsubstituted 6- to 10-membered aryl and the substituted or unsubstituted 5- to 10-membered heteroaryl are selected from at least one of cyano, halogen-substituted or unsubstituted C1-C6 alkyl, and —NR13R14;
• R13 and R14 are independently selected from H and halogen-substituted or unsubstituted C1-C4 alkyl, or R13 and R14, together with the N atom in —NR13R14, form a halogen-substituted or unsubstituted 3- to 8-membered heterocycloalkyl, wherein the 3- to 8-membered heterocycloalkyl, in addition to the aforementioned N atom, further contains 0 to 2 heteroatoms selected from N, S, and O;
• ring B is selected from
• R2 to R6 are independently selected from H, halogen, halogen-substituted or unsubstituted C1-C8 alkyl, and halogen-substituted or unsubstituted C1-C8 alkoxy;
• R7 to R9 and R11 are independently selected from H, halogen, and halogen-substituted or unsubstituted C1-C6 alkyl;
• R10 and R12 are independently selected from substituted or unsubstituted 6- to 10-membered aryl and substituted or unsubstituted 5- to 10-membered heteroaryl;
• in R10 and R12, the 5- to 10-membered heteroaryl contains 1 to 3 heteroatoms, wherein the heteroatoms are selected from N, S, and O;
• in R10 and R12, the substituents of the substituted 6- to 10-membered aryl and the substituted 5- to 10-membered heteroaryl are selected from cyano, halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, —NR15R16, and —SO2R17;
• in R10 and R12, the substituents of the substituted C1-C6 alkyl and the substituted C1-C6 alkoxy are selected from hydroxyl and halogen;
• R15, R16, and R17 are independently selected from H and halogen-substituted or unsubstituted C1-C4 alkyl;
• X is selected from a bond and —CH(R18)(CH2)n—;
• wherein n is an integer from 0 to 3;
• R18 is selected from H and C1-C4 alkyl;
• Y is selected from
• R19 and R20 are independently selected from H, hydroxyl, cyano, halogen, and halogen-substituted or unsubstituted C1-C4 alkyl;
• Z and W are independently selected from N and CR21;
• R21 is selected from H and halogen.